1021. HIV-1 RNA Blips and Low-Level Replication During Phase III/IIIb Cabotegravir + Rilpivirine Long-Acting Studies Are Similar to Oral 3-Drug Therapy and Not Associated with Week...

por Talarico, Christine L, Wu, Sterling, Upadhyay, Ojesh R, Clair, Marty St, Van Eygen, Veerle, Hudson, Krischan J, Griffith, Sandy, Harrington, Conn M, van Lunzen, Jan, Margolis, David, Spreen, William
Publicado 2020

877. North American Phase 3/3b Experience with Long-Acting Cabotegravir and Rilpivirine: Efficacy, Safety, and Virologic Outcomes

por Taiwo, Babafemi O, Tan, Darrell, Patel, Parul, Teichner, Paula, Polli, Joseph, Garside, Louise, D’Amico, Ronald, Talarico, Christine L, Van Solingen-Ristea, Rodica, Baugh, Bryan, Spreen, William, Aboud, Michael, Bosse, Matthew
Publicado 2021

1587. SOLAR 12-Month North American Results: Randomized Switch Trial of CAB+RPV LA vs. Oral BIC/FTC/TAF

por McKellar, Mehri, Teichner, Paula, Bettacchi, Christopher, Angel, Jonathan, Gordon, Lori A, Sutton, Kenneth, Sutherland-Phillips, Denise, Talarico, Christine L, Urbaityte, Rimgaile, Solingen-Ristea, Rodica Van, Baugh, Bryan, D’Amico, Ronald, van Wyk, Jean A
Publicado 2023

Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment

por Swindells, Susan, Lutz, Thomas, Van Zyl, Lelanie, Porteiro, Norma, Stoll, Matthias, Mitha, Essack, Shon, Alyssa, Benn, Paul, Huang, Jenny O., Harrington, Conn M., Hove, Kai, Ford, Susan L., Talarico, Christine L., Chounta, Vasiliki, Crauwels, Herta, Van Solingen-Ristea, Rodica, Vanveggel, Simon, Margolis, David A., Smith, Kimberly Y., Vandermeulen, Kati, Spreen, William R.
Publicado 2022

Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis

por Cutrell, Amy G., Schapiro, Jonathan M., Perno, Carlo F., Kuritzkes, Daniel R., Quercia, Romina, Patel, Parul, Polli, Joseph W., Dorey, David, Wang, Yongwei, Wu, Sterling, Van Eygen, Veerle, Crauwels, Herta, Ford, Susan L., Baker, Mark, Talarico, Christine L., Clair, Marty St, Jeffrey, Jerry, White, C. Thomas, Vanveggel, Simon, Vandermeulen, Kati, Margolis, David A., Aboud, Michael, Spreen, William R., van Lunzen, Jan
Publicado 2021

Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials

por Rizzardini, Giuliano, Overton, Edgar T., Orkin, Chloe, Swindells, Susan, Arasteh, Keikawus, Górgolas Hernández-Mora, Miguel, Pokrovsky, Vadim, Girard, Pierre-Marie, Oka, Shinichi, Andrade-Villanueva, Jaime F., Richmond, Gary J., Baumgarten, Axel, Masiá, Mar, Latiff, Gulam, Griffith, Sandy, Harrington, Conn M., Hudson, Krischan J., St. Clair, Marty, Talarico, Christine L., Patel, Parul, Cutrell, Amy, Van Eygen, Veerle, D'Amico, Ronald, Mrus, Joseph M., Wu, Sterling, Ford, Susan L., Chow, Ken, Roberts, Jeremy, Wills, Angela, Walters, Nicola, Vanveggel, Simon, Van Solingen-Ristea, Rodica, Crauwels, Herta, Smith, Kimberly Y., Spreen, William R., Margolis, David A.
Publicado 2020